Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus

Clinical Chemistry

Volumn 57, Issue 6, 2011, Pages

  Sacks, David B ^a   Arnold, Mark ^b   Bakris, George L ^c   Bruns, David E ^d   Horvath, Andrea Rita ^e   Kirkman, M Sue ^f   Lernmark, Ake ^g   Metzger, Boyd E ^h   Nathan, David M ⁱ  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b E11 SSH   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d UNIVERSITY OF VIRGINIA   (United States)

^e UNIVERSITY OF SYDNEY   (Australia)

^f AMERICAN DIABETES ASSOCIATION   (United States)

^g LUND UNIVERSITY   (Sweden)

^h NORTHWESTERN UNIVERSITY   (United States)

ⁱ MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXYBUTYRIC ACID; ACETOACETIC ACID; ACETONE; ADVANCED GLYCATION END PRODUCT; ALBUMIN; AMYLIN; C PEPTIDE; CREATININE; EDETIC ACID; FLUORIDE SODIUM; GLUCOSE; GLUTAMATE DECARBOXYLASE 65; HEMOGLOBIN A1C; HLA A ANTIGEN; HLA B ANTIGEN; HLA DQA1 ANTIGEN; HLA DQB1 ANTIGEN; INSULIN; INSULIN ANTIBODY; LEPTIN; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 22; ORAL ANTIDIABETIC AGENT; PROINSULIN;

ALBUMINURIA; BLOOD GLUCOSE METER; BLOOD GLUCOSE MONITORING; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DIABETIC DIET; DIABETIC KETOACIDOSIS; DIABETIC NEPHROPATHY; GENETIC ASSOCIATION; GENETIC SCREENING; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; GLYCOLYSIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN TREATMENT; LABORATORY TEST; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PRACTICE GUIDELINE; PREGNANCY DIABETES MELLITUS; PROTEIN URINE LEVEL; REVIEW; TURNAROUND TIME;

ALBUMINURIA; AUTOANTIBODIES; BLOOD GLUCOSE; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETES, GESTATIONAL; DISEASE MANAGEMENT; EVIDENCE-BASED MEDICINE; FEMALE; GENETIC MARKERS; GLYCOSURIA; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; ISLETS OF LANGERHANS; KETONE BODIES; MONITORING, PHYSIOLOGIC; PREGNANCY; PROGNOSIS; REFERENCE VALUES;

EID: 79957715132     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2010.161596     Document Type: Review

References (378)

1. ADA. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20:1183-97.
2. Castano L, Eisenbarth GS. Type-I diabetes: a chronic autoimmune disease of human, mouse, and rat. Annu Rev Immunol 1990;8:647-79. (Pubitemid 20135642)
3. Reaven GM. Banting Lecture 1988. Role of insulin resistance in human disease. Diabetes 1988;37:1595-607. (Pubitemid 19004941)
4. Sacks DB, McDonald JM. The pathogenesis of type II diabetes mellitus. A polygenic disease. Am J Clin Pathol 1996;105:149-56. (Pubitemid 26047473)
5. Balasubramanyam A, Garza G, Rodriguez L, Hampe CS, Gaur L, Lernmark A, Maldonado MR. Accuracy and predictive value of classification schemes for ketosis-prone diabetes. Diabetes Care 2006;29:2575-9. (Pubitemid 44912181)
6. IDF. Diabetes atlas. 3rd ed. Brussels: IDF; 2008.
7. Cowie CC, Rust KF, Byrd-Holt DD, Eberhardt MS, Flegal KM, Engelgau MM, et al. Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population: National Health and Nutrition Examination Survey 1999-2002. Diabetes Care 2006;29:1263-8.
8. Cowie CC, Rust KF, Ford ES, Eberhardt MS, Byrd-Holt DD, Li C, et al. Full accounting of diabetes and pre-diabetes in the U.S. population in 1988-1994 and 2005-2006. Diabetes Care 2009;32:287-94.
9. Chan JC, Malik V, Jia W, Kadowaki T, Yajnik CS, Yoon KH, Hu FB. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA 2009;301:2129-40.
10. Yang W, Lu J, Weng J, Jia W, Ji L, Xiao J, et al. Prevalence of diabetes among men and women in China. N Engl J Med 2010;362:1090-101.
11. ADA. Economic costs of diabetes in the U.S. in 2007. Diabetes Care 2008;31:596-615.
12. Nathan DM. Long-term complications of diabetes mellitus. N Engl J Med 1993;328:1676-85. (Pubitemid 23157351)
13. Roglic G, Unwin N, Bennett PH, Mathers C, Tuomilehto J, Nag S, et al. The burden of mortality attributable to diabetes: realistic estimates for the year 2000. Diabetes Care 2005;28:2130-5.
14. Sacks DB, Bruns DE, Goldstein DE, Maclaren NK, McDonald JM, Parrott M. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin Chem 2002;48:436-72. (Pubitemid 34174577)
15. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979;28:1039-57.
16. WHO. WHO Expert Committee on Diabetes Mellitus: second report. World Health Organ Tech Rep Ser 1980;646:1-80.
17. Engelgau MM, Thompson TJ, Herman WH, Boyle JP, Aubert RE, Kenny SJ, et al. Comparison of fasting and 2-hour glucose and HbA1c levels for diagnosing diabetes. Diagnostic criteria and performance revisited. Diabetes Care 1997;20:785-91.
18. McCance DR, Hanson RL, Charles MA, Jacobsson LT, Pettitt DJ, Bennett PH, Knowler WC. Comparison of tests for glycated haemoglobin and fasting and two hour plasma glucose concentrations as diagnostic methods for diabetes. BMJ 1994;308:1323-8.
19. WHO. Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia: report of a WHO/IDF consultation. Geneva: WHO; 2006.
20. The International Expert Committee. International Expert Committee report on the role of the A1c assay in the diagnosis of diabetes. Diabetes Care 2009;32:1327-34.
21. ADA. Standards of medical care in diabetes - 2010. Diabetes Care 2010;33(Suppl 1):S11-61.
22. ADA. Tests of glycemia in diabetes. Diabetes Care 2001;24(Suppl 1):S80-2.
23. IDF. Task Force. Global guideline for type 2 diabetes. Brussels: IDF; 2005. p 1-11.
24. Saudek CD, Herman WH, Sacks DB, Bergenstal RM, Edelman D, Davidson MB. A new look at screening and diagnosing diabetes mellitus. J Clin Endocrinol Metab 2008;93:2447-53. (Pubitemid 352008502)
25. ADA. Type 2 diabetes in children and adolescents. Diabetes Care 2000;23:381-9.
26. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403. (Pubitemid 34437694)
27. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343-50. (Pubitemid 32378388)
28. Icks A, Rathmann W, Haastert B, John J, Löwel H, Holle R, Giani G. Cost-effectiveness of type 2 diabetes screening: results from recently published studies. Gesundheitswesen 2005; 67(Suppl 1):S167-71.
29. Perry RC, Shankar RR, Fineberg N, McGill J, Baron AD. HbA1c measurement improves the detection of type 2 diabetes in high-risk individuals with nondiagnostic levels of fasting plasma glucose: the Early Diabetes Intervention Program (EDIP). Diabetes Care 2001;24:465-71. (Pubitemid 32198414)
30. 1c for cost-effective screening. Diabetes Care 2003;26:485-90.
31. Dallo FJ, Weller SC. Effectiveness of diabetes mellitus screening recommendations. Proc Natl Acad Sci U S A 2003;100:10574-9. (Pubitemid 37071920)
32. Diabetes Cost-Effectiveness Study Group, Centers for Disease Control and Prevention. The cost-effectiveness of screening for type 2 diabetes. JAMA 1998;280:1757-63.
33. Hoerger TJ, Harris R, Hicks KA, Donahue K, Sorensen S, Engelgau M. Screening for type 2 diabetes mellitus: a cost-effectiveness analysis. Ann Intern Med 2004;140:689-99.
34. Glumer C, Yuyun M, Griffin S, Farewell D, Spiegelhalter D, Kinmonth AL, Wareham NJ. What determines the cost-effectiveness of diabetes screening? Diabetologia 2006;49:1536-44.
35. Kahn R, Alperin P, Eddy D, Borch-Johnsen K, Buse J, Feigelman J, et al. Age at initiation and frequency of screening to detect type 2 diabetes: a cost-effectiveness analysis. Lancet 2010;375:1365-74.
36. Greenberg RA, Sacks DB. Screening for diabetes: is it warranted? Clin Chim Acta 2002;315:61-9.
37. Genuth S, Alberti KG, Bennett P, Buse J, Defronzo R, Kahn R, et al. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003;26:3160-7. (Pubitemid 37339514)
38. Forouhi NG, Balkau B, Borch-Johnsen K, Dekker J, Glumer C, Qiao Q, et al. The threshold for diagnosing impaired fasting glucose: a position statement by the European Diabetes Epidemiology Group. Diabetologia 2006;49:822-7.
39. Tai ES, Goh SY, Lee JJ, Wong MS, Heng D, Hughes K, et al. Lowering the criterion for impaired fasting glucose: impact on disease prevalence and associated risk of diabetes and ischemic heart disease. Diabetes Care 2004;27:1728-34. (Pubitemid 38857451)
40. Gabir MM, Hanson RL, Dabelea D, Imperatore G, Roumain J, Bennett PH, Knowler WC. The 1997 American Diabetes Association and 1999 World Health Organization criteria for hyperglycemia in the diagnosis and prediction of diabetes. Diabetes Care 2000;23:1108-12.
41. Tirosh A, Shai I, Tekes-Manova D, Israeli E, Pereg D, Shochat T, et al. Normal fasting plasma glucose levels and type 2 diabetes in young men. N Engl J Med 2005;353:1454-62. (Pubitemid 41400919)
42. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes 1995;44:968-83.
43. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-12. (Pubitemid 30609442)
44. DCCT. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86.
45. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643-53. (Pubitemid 41817713)
46. UKPDS Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
47. Selvin E, Marinopoulos S, Berkenblit G, Rami T, Brancati FL, Powe NR, Golden SH. Metaanalysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 2004;141:421-31.
48. Ray KK, Seshasai SR, Wijesuriya S, Sivakumaran R, Nethercott S, Preiss D, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 2009;373:1765-72.
49. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-89.
50. Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-59. (Pubitemid 351831356)
51. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-72. (Pubitemid 351831357)
52. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360:129-39.
53. Berg AH, Sacks DB. Haemoglobin A1c analysis in the management of patients with diabetes: from chaos to harmony. J Clin Pathol 2008;61:983-7.
54. Howe-Davies S, Simpson RW, Turner RC. Control of maturity-onset diabetes by monitoring fasting blood glucose and body weight. Diabetes Care 1980;3:607-10. (Pubitemid 11245826)
55. Muir A, Howe-Davies SA, Turner RC. General practice care of non-insulin-dependent diabetes with fasting blood glucose measurements. Am J Med 1982;73:637-40. (Pubitemid 13234216)
56. Harris MI. Undiagnosed NIDDM: clinical and public health issues. Diabetes Care 1993;16:642-52.
57. Troisi RJ, Cowie CC, Harris MI. Diurnal variation in fasting plasma glucose: implications for diagnosis of diabetes in patients examined in the afternoon. JAMA 2000;284:3157-9. (Pubitemid 32039079)
58. Bruns DE, Knowler WC. Stabilization of glucose in blood samples: why it matters. Clin Chem 2009;55:850-2.
59. Chan AY, Swaminathan R, Cockram CS. Effectiveness of sodium fluoride as a preservative of glucose in blood. Clin Chem 1989;35:315-7. (Pubitemid 19075618)
60. Ladenson JH. Nonanalytical sources of variation in clinical chemistry results. In: Sonnenwirth A, Jarett L, eds. Clinical laboratory methods and diagnosis. St. Louis: C.V. Mosby Co.; 1980. p 149-92.
61. Sacks DB. Carbohydrates. In: Burtis CA, Ashwood ER, Bruns DE, eds. Tietz textbook of clinical chemistry and molecular diagnostics. 4th ed. St. Louis: Elsevier Saunders; 2006. p 837-902.
62. Gambino R, Piscitelli J, Ackattupathil TA, Theriault JL, Andrin RD, Sanfilippo ML, Etienne M. Acidification of blood is superior to sodium fluoride alone as an inhibitor of glycolysis. Clin Chem 2009;55:1019-21.
63. Ladenson JH, Tsai LM, Michael JM, Kessler G, Joist JH. Serum versus heparinized plasma for eighteen common chemistry tests: Is serum the appropriate specimen? Am J Clin Pathol 1974;62:545-52.
64. Stahl M, Jorgensen LG, Hyltoft Petersen P, Brandslund I, de Fine Olivarius N, Borch-Johnsen K. Optimization of preanalytical conditions and analysis of plasma glucose. 1. Impact of the new WHO and ADA recommendations on diagnosis of diabetes mellitus. Scand J Clin Lab Invest 2001;61:169-79.
65. Carstensen B, Lindstrom J, Sundvall J, Borch-Johnsen K, Tuomilehto J. Measurement of blood glucose: comparison between different types of specimens. Ann Clin Biochem 2008;45:140-8. (Pubitemid 351724584)
66. Boyanton BL Jr, Blick KE. Stability studies of twenty-four analytes in human plasma and serum. Clin Chem 2002;48:2242-7. (Pubitemid 35397569)
67. Miles RR, Roberts RF, Putnam AR, Roberts WL. Comparison of serum and heparinized plasma samples for measurement of chemistry analytes. Clin Chem 2004;50:1704-5.
68. Larsson-Cohn U. Differences between capillary and venous blood glucose during oral glucose tolerance tests. Scand J Clin Lab Invest 1976;36:805-8.
69. Lind T, de Groot HA, Brown G, Cheyne GA. Observations on blood glucose and insulin determinations. Br Med J 1972;3:320-3.
70. Sacks DB. Carbohydrates. In: Burtis CA, Ashwood ER, Bruns DE, eds. Tietz textbook of clinical chemistry and molecular diagnostics. 5th ed. St. Louis: Elsevier Saunders. Accepted; forth-coming 2012.
71. Tchobroutsky G. Blood glucose levels in diabetic and non-diabetic subjects. Diabetologia 1991;34:67-73.
72. Blunt BA, Barrett-Connor E, Wingard DL. Evaluation of fasting plasma glucose as screening test for NIDDM in older adults. Rancho Bernardo Study. Diabetes Care 1991;14:989-93.
73. DECODE. Consequences of the new diagnostic criteria for diabetes in older men and women. DECODE Study (Diabetes Epidemiology: Collaborative Analysis of Diagnostic Criteria in Europe). Diabetes Care 1999;22:1667-71.
74. Ferrannini E, Vichi S, Beck-Nielsen H, Laakso M, Paolisso G, Smith U. Insulin action and age. European Group for the Study of Insulin Resistance (EGIR). Diabetes 1996;45:947-53. (Pubitemid 26225512)
75. Imbeault P, Prins JB, Stolic M, Russell AW, O'Moore-Sullivan T, Despres JP, et al. Aging per se does not influence glucose homeostasis: in vivo and in vitro evidence. Diabetes Care 2003;26:480-4. (Pubitemid 36929078)
76. Miller WG, Myers GL, Ashwood ER, Killeen AA, Wang E, Ehlers GW, et al. State of the art in trueness and interlaboratory harmonization for 10 analytes in general clinical chemistry. Arch Pathol Lab Med 2008;132:838-46. (Pubitemid 351632864)
77. Fraser CG, Petersen PH. Analytical performance characteristics should be judged against objective quality specifications. Clin Chem 1999;45:321-3. (Pubitemid 29114165)
78. Stockl D, Baadenhuijsen H, Fraser CG, Libeer JC, Petersen PH, Ricos C. Desirable routine analytical goals for quantities assayed in serum. Discussion paper from the members of the External Quality Assessment (EQA) Working Group A on analytical goals in laboratory medicine. Eur J Clin Chem Clin Biochem 1995;33:157-69.
79. Fraser CG. The necessity of achieving good laboratory performance. Diabet Med 1990;7:490-3. (Pubitemid 20199792)
80. Olefsky JM, Reaven GM. Insulin and glucose responses to identical oral glucose tolerance tests performed forty-eight hours apart. Diabetes 1974;23:449-53.
81. Widjaja A, Morris RJ, Levy JC, Frayn KN, Manley SE, Turner RC. Within-and between-subject variation in commonly measured anthropometric and biochemical variables. Clin Chem 1999;45:561-6. (Pubitemid 29165967)
82. Sebastian-Gambaro MA, Liron-Hernandez FJ, Fuentes-Arderiu X. Intra-and inter-individual biological variability data bank. Eur J Clin Chem Clin Biochem 1997;35:845-52. (Pubitemid 27510862)
83. Mooy JM, Grootenhuis PA, de Vries H, Kostense PJ, Popp-Snijders C, Bouter LM, Heine RJ. Intraindividual variation of glucose, specific insulin and proinsulin concentrations measured by two oral glucose tolerance tests in a general Caucasian population: the Hoorn Study. Diabetologia 1996;39:298-305. (Pubitemid 26066801)
84. Selvin E, Crainiceanu CM, Brancati FL, Coresh J. Short-term variability in measures of glycemia and implications for the classification of diabetes. Arch Intern Med 2007;167:1545-51. (Pubitemid 47124186)
85. Lacher DA, Hughes JP, Carroll MD. Estimate of biological variation of laboratory analytes based on the Third National Health and Nutrition Examination Survey. Clin Chem 2005;51:450-2. (Pubitemid 40175818)
86. Westgard QC. Desirable specifications for total error, imprecision, and bias, derived from biologic variation. http://www.westgard.com/biodatabase1.htm (Accessed July 2009).
87. Howanitz PJ, Cembrowski GS, Steindel SJ, Long TA. Physician goals and laboratory test turnaround times. A College of American Pathologists Q-Probes study of 2763 clinicians and 722 institutions. Arch Pathol Lab Med 1993;117:22-8.
88. van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, et al. Intensive insulin therapy in the critically ill patients. N Engl J Med 2001;345:1359-67.
89. ADA. Standards of medical care in diabetes - 2009. Diabetes Care 2009;32(Suppl 1):S13-61.
90. Harris MI, Cowie CC, Howie LJ. Self-monitoring of blood glucose by adults with diabetes in the United States population. Diabetes Care 1993;16:1116-23. (Pubitemid 23215399)
91. CDC. Self-monitoring of blood glucose among adults with diabetes - United States, 1997-2006. MMWR Morb Mortal Wkly Rep 2007;56:1133-7.
92. ADA. Self-monitoring of blood glucose. Diabetes Care 1996;19(Suppl 1):S62-6.
93. ADA. Standards of medical care in diabetes-2011. Diabetes Care 2011;34(Suppl 1):S11-61.
94. Ipp E, Aquino RL, Christenson P. Point: Self-monitoring of blood glucose in type 2 diabetic patients not receiving insulin: the sanguine approach. Diabetes Care 2005;28:1528-30. (Pubitemid 40756732)
95. Davidson MB. Counterpoint: Self-monitoring of blood glucose in type 2 diabetic patients not receiving insulin: a waste of money. Diabetes Care 2005;28:1531-3. (Pubitemid 40756733)
96. Faas A, Schellevis FG, Van Eijk JT. The efficacy of self-monitoring of blood glucose in NIDDM subjects. A criteria-based literature review. Diabetes Care 1997;20:1482-6.
97. Coster S, Gulliford MC, Seed PT, Powrie JK, Swaminathan R. Self-monitoring in type 2 diabetes mellitus: a meta-analysis. Diabet Med 2000;17:755-61. (Pubitemid 32000973)
98. Harris MI. Frequency of blood glucose monitoring in relation to glycemic control in patients with type 2 diabetes. Diabetes Care 2001;24:979-82. (Pubitemid 33716362)
99. Davis WA, Bruce DG, Davis TM. Is selfmonitoring of blood glucose appropriate for all type 2 diabetic patients? The Fremantle Diabetes Study. Diabetes Care 2006;29:1764-70. (Pubitemid 44156627)
100. Guerci B, Drouin P, Grange V, Bougneres P, Fontaine P, Kerlan V, et al. Self-monitoring of blood glucose significantly improves metabolic control in patients with type 2 diabetes mellitus: the Auto-Surveillance Intervention Active (ASIA) study. Diabetes Metab 2003;29:587-94. (Pubitemid 38082160)
101. Davidson MB, Castellanos M, Kain D, Duran P. The effect of self monitoring of blood glucose concentrations on glycated hemoglobin levels in diabetic patients not taking insulin: a blinded, randomized trial. Am J Med 2005;118:422-5. (Pubitemid 40461003)
102. Franciosi M, Pellegrini F, De Berardis G, Belfiglio M, Di Nardo B, Greenfield S, et al. Selfmonitoring of blood glucose in non-insulintreated diabetic patients: a longitudinal evaluation of its impact on metabolic control. Diabet Med 2005;22:900-6. (Pubitemid 40942589)
103. Karter AJ, Parker MM, Moffet HH, Spence MM, Chan J, Ettner SL, Selby JV. Longitudinal study of new and prevalent use of self-monitoring of blood glucose. Diabetes Care 2006;29:1757-63. (Pubitemid 44156626)
104. Martin S, Schneider B, Heinemann L, Lodwig V, Kurth HJ, Kolb H, Scherbaum WA. Self-monitoring of blood glucose in type 2 diabetes and long-term outcome: an epidemiological cohort study. Diabetologia 2006;49:271-8. (Pubitemid 43185395)
105. Welschen LM, Bloemendal E, Nijpels G, Dekker JM, Heine RJ, Stalman WA, Bouter LM. Self-monitoring of blood glucose in patients with type 2 diabetes who are not using insulin. Cochrane Database Syst Rev 2005:CD005060.
106. Welschen LM, Bloemendal E, Nijpels G, Dekker JM, Heine RJ, Stalman WA, Bouter LM. Self-monitoring of blood glucose in patients with type 2 diabetes who are not using insulin: a systematic review. Diabetes Care 2005;28:1510-7. (Pubitemid 40756728)
107. Farmer A, Wade A, Goyder E, Yudkin P, French D, Craven A, et al. Impact of self monitoring of blood glucose in the management of patients with non-insulin treated diabetes: open parallel group randomised trial. BMJ 2007;335:132.
108. Simon J, Gray A, Clarke P, Wade A, Neil A, Farmer A. Cost effectiveness of self monitoring of blood glucose in patients with non-insulin treated type 2 diabetes: economic evaluation of data from the DiGEM trial. BMJ 2008;336:1177-80. (Pubitemid 351809279)
109. O'Kane MJ, Bunting B, Copeland M, Coates VE. Efficacy of self monitoring of blood glucose in patients with newly diagnosed type 2 diabetes (ESMON study): randomised controlled trial. BMJ 2008;336:1174-7. (Pubitemid 351809278)
110. Allemann S, Houriet C, Diem P, Stettler C. Self-monitoring of blood glucose in non-insulin treated patients with type 2 diabetes: a systematic review and meta-analysis. Curr Med Res Opin 2009;25:2903-13.
111. Poolsup N, Suksomboon N, Rattanasookchit S. Meta-analysis of the benefits of self-monitoring of blood glucose on glycemic control in type 2 diabetes patients: an update. Diabetes Technol Ther 2009;11:775-84.
112. Montori VM, Fernández-Balsells M. Glycemic control in type 2 diabetes: time for an evidence-based about-face? Ann Intern Med 2009;150:803-8.
113. Gerich JE, Mokan M, Veneman T, Korytkowski M, Mitrakou A. Hypoglycemia unawareness. Endocr Rev 1991;12:356-71.
114. Tang Z, Lee JH, Louie RF, Kost GJ. Effects of different hematocrit levels on glucose measurements with handheld meters for point-of-care testing. Arch Pathol Lab Med 2000;124:1135-40. (Pubitemid 30650312)
115. ADA. Consensus statement on self-monitoring of blood glucose. Diabetes Care 1994;17:81-6.
116. Tate PF, Clements CA, Walters JE. Accuracy of home blood glucose monitors. Diabetes Care 1992;15:536-8.
117. Chan JC, Wong RY, Cheung CK, Lam P, Chow CC, Yeung VT, et al. Accuracy, precision and user-acceptability of self blood glucose monitoring machines. Diabetes Res Clin Pract 1997;36:91-104. (Pubitemid 27297002)
118. Kabadi UM, O'Connell KM, Johnson J, Kabadi M. The effect of recurrent practice at home on the acceptability of capillary blood glucose readings. Accuracy of self blood glucose testing. Diabetes Care 1994;17:1110-23.
119. Burnett RW, D'Orazio P, Fogh-Andersen N, Kuwa K, Kulpmann WR, Larsson L, et al. IFCC recommendation on reporting results for blood glucose. Clin Chim Acta 2001;307:205-9. (Pubitemid 32448926)
120. D'Orazio P, Burnett RW, Fogh-Andersen N, Jacobs E, Kuwa K, Kulpmann WR, et al. Approved IFCC recommendation on reporting results for blood glucose (abbreviated). Clin Chem 2005;51:1573-6. (Pubitemid 41233089)
121. Steffes MW, Sacks DB. Measurement of circulating glucose concentrations: The time is now for consistency among methods and types of samples. Clin Chem 2005;51:1569-70. (Pubitemid 41233087)
122. Weitgasser R, Gappmayer B, Pichler M. Newer portable glucose meters - analytical improvement compared with previous generation devices? Clin Chem 1999;45:1821-5.
123. Bohme P, Floriot M, Sirveaux MA, Durain D, Ziegler O, Drouin P, Guerci B. Evolution of analytical performance in portable glucose meters in the last decade. Diabetes Care 2003;26:1170-5. (Pubitemid 36929267)
124. Skeie S, Thue G, Nerhus K, Sandberg S. Instruments for self-monitoring of blood glucose: comparisons of testing quality achieved by patients and a technician. Clin Chem 2002;48:994-1003. (Pubitemid 34680893)
125. ADA. Consensus statement on self-monitoring of blood glucose. Diabetes Care 1987;10:93-9.
126. NCCLS. Ancillary (bedside) blood glucose testing in acute and chronic care facilities; approved guideline C30-A. Villanova (PA): NCCLS; 1994;14:1-14.
127. ISO. In vitro diagnostic test systems - requirements for blood-glucose monitoring systems for self-testing in managing diabetes mellitus. Geneva: ISO; 2003. ISO 15197:2003; 1st ed. 2003-05-01.
128. Clarke WL, Cox D, Gonder-Frederick LA, Carter W, Pohl SL. Evaluating clinical accuracy of systems for self-monitoring of blood glucose. Diabetes Care 1987;10:622-8. (Pubitemid 17158937)
129. Skeie S, Thue G, Sandberg S. Patient-derived quality specifications for instruments used in self-monitoring of blood glucose. Clin Chem 2001;47:67-73. (Pubitemid 32064277)
130. Boyd JC, Bruns DE. Quality specifications for glucose meters: assessment by simulation modeling of errors in insulin dose. Clin Chem 2001;47:209-14. (Pubitemid 32142918)
131. Novis DA, Jones BA. Interinstitutional comparison of bedside blood glucose monitoring program characteristics, accuracy performance, and quality control documentation: a College of American Pathologists Q-Probes study of bedside blood glucose monitoring performed in 226 small hospitals. Arch Pathol Lab Med 1998;122:495-502. (Pubitemid 28262179)
132. Brunner GA, Ellmerer M, Sendlhofer G, Wutte A, Trajanoski Z, Schaupp L, et al. Validation of home blood glucose meters with respect to clinical and analytical approaches. Diabetes Care 1998;21:585-90. (Pubitemid 28172939)
133. Weinzimer SA, Beck RW, Chase HP, Fox LA, Buckingham BA, Tamborlane WV, et al. Accuracy of newer-generation home blood glucose meters in a Diabetes Research in Children Network (DirecNet) inpatient exercise study. Diabetes Technol Ther 2005;7:675-80; discussion 681-3.
134. Mahoney J, Ellison J. Assessing the quality of glucose monitor studies: a critical evaluation of published reports. Clin Chem 2007;53:1122-8. (Pubitemid 46867530)
135. Kristensen GB, Nerhus K, Thue G, Sandberg S. Standardized evaluation of instruments for self-monitoring of blood glucose by patients and a technologist. Clin Chem 2004;50:1068-71. (Pubitemid 38725800)
136. Wiener RS, Wiener DC, Larson RJ. Benefits and risks of tight glucose control in critically ill adults: a meta-analysis. JAMA 2008;300:933-44.
137. Scott MG, Bruns DE, Boyd JC, Sacks DB. Tight glucose control in the intensive care unit: Are glucose meters up to the task? Clin Chem 2009;55:18-20.
138. Dungan K, Chapman J, Braithwaite SS, Buse J. Glucose measurement: confounding issues in setting targets for inpatient management. Diabetes Care 2007;30:403-9. (Pubitemid 46198356)
139. Boyd JC, Bruns DE. Monte Carlo simulation in establishing analytical quality requirements for clinical laboratory tests meeting clinical needs. Methods Enzymol 2009;467:411-33.
140. Finkielman JD, Oyen LJ, Afessa B. Agreement between bedside blood and plasma glucose measurement in the ICU setting. Chest 2005;127:1749-51. (Pubitemid 46218804)
141. Hoedemaekers CW, Klein Gunnewiek JM, Prinsen MA, Willems JL, Van der Hoeven JG. Accuracy of bedside glucose measurement from three glucometers in critically ill patients. Crit Care Med 2008;36:3062-6.
142. Meynaar IA, van Spreuwel M, Tangkau PL, Dawson L, Sleeswijk Visser S, et al. Accuracy of AccuChek glucose measurement in intensive care patients. Crit Care Med 2009;37:2691-6.
143. Kanji S, Buffie J, Hutton B, Bunting PS, Singh A, McDonald K, et al. Reliability of point-of-care testing for glucose measurement in critically ill adults. Crit Care Med 2005;33:2778-85. (Pubitemid 41816412)
144. Schiffrin A, Belmonte M. Multiple daily self-glucose monitoring: its essential role in longterm glucose control in insulin-dependent diabetic patients treated with pump and multiple subcutaneous injections. Diabetes Care 1982;5:479-84. (Pubitemid 12015085)
145. Nathan D. The importance of intensive supervision in determining the efficacy of insulin pump therapy. Diabetes Care 1983;6:295-7. (Pubitemid 13096164)
146. de Veciana M, Major CA, Morgan MA, Asrat T, Toohey JS, Lien JM, Evans AT. Postprandial versus preprandial blood glucose monitoring in women with gestational diabetes mellitus requiring insulin therapy. N Engl J Med 1995;333:1237-41.
147. Goldstein DE, Little RR, Lorenz RA, Malone JI, Nathan D, Peterson CM, Sacks DB. Tests of glycemia in diabetes. Diabetes Care 2004;27:1761-73. (Pubitemid 38857461)
148. Garg S, Zisser H, Schwartz S, Bailey T, Kaplan R, Ellis S, Jovanovic L. Improvement in glycemic excursions with a transcutaneous, real-time continuous glucose sensor: a randomized controlled trial. Diabetes Care 2006;29:44-50. (Pubitemid 44033429)
149. Chetty VT, Almulla A, Odueyungbo A, Thabane L. The effect of continuous subcutaneous glucose monitoring (CGMS) versus intermittent whole blood finger-stick glucose monitoring (SBGM) on hemoglobin A1c (HBA1c) levels in type I diabetic patients: a systematic review. Diabetes Res Clin Pract 2008;81:79-87.
150. Tamborlane WV, Beck RW, Bode BW, Buckingham B, Chase HP, Clemons R, et al. Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med 2008;359:1464-76.
151. Haupt K, Mosbach K. Plastic antibodies: developments and applications. Trends Biotechnol 1998;16:468-75. (Pubitemid 28532703)
152. Chen G, Guan Z, Chen CT, Fu L, Sundaresan V, Arnold FH. A glucose-sensing polymer. Nat Biotechnol 1997;15:354-7. (Pubitemid 27150251)
153. James TD, Sandanayake KRAS, Shinkai S. A glucose-selective molecular fluorescence sensor. Angew Chem Int Ed Engl 1994;33:2207-9. (Pubitemid 24986814)
154. Birch DJS, Imhof RE. Time-domain fluorescence spectroscopy using time-correlated singlephoton counting. Top Fluoresc Spectrosc 1994;1:1-95.
155. Tolosa L, Szmacinski H, Rao G, Lakowicz JR. Lifetime-based sensing of glucose using energy transfer with a long lifetime donor. Anal Biochem 1997;250:102-8. (Pubitemid 27310318)
156. Rolinski OJ, Birch DJS, McCartney LJ, Pickup JC. Near-infrared assay for glucose determination. Proc Soc Photo Opt Instrum Eng 1999;3602:6-14.
157. Marvin JS, Hellinga HW. Engineering biosensors by introducing fluorescent allosteric signal transducers: construction of a novel glucose sensor. J Am Chem Soc 1998;120:7-11. (Pubitemid 28046421)
158. Wentholt IM, Vollebregt MA, Hart AA, Hoekstra JB, DeVries JH. Comparison of a needle-type and a microdialysis continuous glucose monitor in type 1 diabetic patients. Diabetes Care 2005;28:2871-6. (Pubitemid 43942917)
159. Khalil OS. Non-invasive glucose measurement technologies: an update from 1999 to the dawn of the new millennium. Diabetes Technol Ther 2004;6:660-97.
160. Arnold MA, Small GW. Noninvasive glucose sensing. Anal Chem 2005;77:5429-39. (Pubitemid 41266033)
161. Tura A, Maran A, Pacini G. Non-invasive glucose monitoring: assessment of technologies and devices according to quantitative criteria. Diabetes Res Clin Pract 2007;77:16-40. (Pubitemid 46590478)
162. Sieg A, Guy RH, Delgado-Charro MB. Noninvasive and minimally invasive
163. Kohl M, Essenpreis M, Cope M. The influence of glucose concentration upon the transport of light in tissue-simulating phantoms. Phys Med Biol 1995;40:1267-87.
164. Heise HM, Lampen P. Transcutaneous glucose measurements using near-infrared spectroscopy: validation of statistical calibration models. Diabetes Care 2000;23:1208-10.
165. Gutman S, Bernhardt P, Pinkos A, Moxey-Mims M, Knott T, Cooper J. Regulatory aspects of noninvasive glucose measurements. Diabetes Technol Ther 2002;4:779-81. (Pubitemid 36169235)
166. Rhiel MH, Amrhein MI, Marison IW, von Stockar U. The influence of correlated calibration samples on the prediction performance of multivariate models based on mid-infrared spectra of animal cell cultures. Anal Chem 2002;74:5227-36. (Pubitemid 35215350)
167. Arnold MA, Liu L, Olesberg JT. Selectivity assessment of noninvasive glucose measurements based on analysis of multivariate calibration vectors. J Diabetes Sci Technol 2007;1:454-62.
168. Small GW. Chemometrics and near-infrared spectroscopy: avoiding the pitfalls. Trends Anal Chem 2006;25:1057-66. (Pubitemid 44821416)
169. Gabrielsson J, Trygg J. Recent developments in multivariate calibration. Crit Rev Anal Chem 2006;36:243-55. (Pubitemid 44889530)
170. Arnold MA, Small GW, Xiang D, Qui J, Murhammer DW. Pure component selectivity analysis of multivariate calibration models from nearinfrared spectra. Anal Chem 2004;76:2583-90. (Pubitemid 38585727)
171. Arnold MA, Olesberg JT, Small GW. Nearinfrared spectroscopy for noninvasive glucose sensing. In: Cunningham D, Stenken JA, eds. Analytical chemistry of in vivo glucose measurements. Hoboken, NJ: John Wiley & Sons; 2009. p 357-90.
172. Shih W-C, Bechtel KB, Feld MS. Noninvasive glucose sensing with Raman spectroscopy. In: Cunningham D, Stenken JA, eds. Analytical chemistry of in vivo glucose measurements. Hoboken, NJ: John Wiley & Sons; 2009. p 391-419.
173. Lawrence JM, Contreras R, Chen W, Sacks DA. Trends in the prevalence of preexisting diabetes and gestational diabetes mellitus among a racially/ethnically diverse population of pregnant women, 1999-2005. Diabetes Care 2008;31:899-904.
174. Crowther CA, Hiller JE, Moss JR, McPhee AJ, Jeffries WS, Robinson JS. Effect of treatment of gestational diabetes mellitus on pregnancy outcomes. N Engl J Med 2005;352:2477-86. (Pubitemid 41007863)
175. Landon MB, Spong CY, Thom E, Carpenter MW, Ramin SM, Casey B, et al. A multicenter, randomized trial of treatment for mild gestational diabetes. N Engl J Med 2009;361:1339-48.
176. Metzger BE, Lowe LP, Dyer AR, Trimble ER, Chaovarindr U, Coustan DR, et al. Hyperglycemia and adverse pregnancy outcomes. N Engl J Med 2008;358:1991-2002.
177. HAPO Study Cooperative Research Group. Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Study: associations with neonatal anthropometrics. Diabetes 2009;58:453-9.
178. International Association of Diabetes and Pregnancy Study Groups. International Association of Diabetes and Pregnancy Study Groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care 2010;33:676-82.
179. Kim C, Newton KM, Knopp RH. Gestational diabetes and the incidence of type 2 diabetes: a systematic review. Diabetes Care 2002;25:1862-8.
180. ADA. Tests of glycemia in diabetes. Diabetes Care 1999;22(Suppl 1):S77-9.
181. Sacks DB. Diabetes mellitus. In: Burtis CA, Ashwood ER, Bruns DE, eds. Tietz textbook of clinical chemistry and molecular diagnostics. 5th ed. St. Louis: Elsevier Saunders. Accepted, forthcoming 2012.
182. Kitabchi AE, Umpierrez GE, Murphy MB, Barrett EJ, Kreisberg RA, Malone JI, Wall BM. Hyperglycemic crises in diabetes. Diabetes Care 2004;27(Suppl 1):S94-102.
183. Kreisberg RA. Diabetic ketoacidosis: new concepts and trends in pathogenesis and treatment. Ann Intern Med 1978;88:681-95. (Pubitemid 8339956)
184. Owen OE, Trapp VE, Skutches CL, Mozzoli MA, Hoeldtke RD, Boden G, Reichard GA Jr. Acetone metabolism during diabetic ketoacidosis. Diabetes 1982;31:242-8. (Pubitemid 12170296)
185. Stephens JM, Sulway MJ, Watkins PJ. Relationship of blood acetoacetate and 3-hydroxybutyrate in diabetes. Diabetes 1971;20:485-9.
186. Porter WH, Yao HH, Karounos DG. Laboratory and clinical evaluation of assays for betahydroxybutyrate. Am J Clin Pathol 1997;107:353-8. (Pubitemid 27090241)
187. ADA. Tests of glycemia in diabetes [Position statement]. Diabetes Care 2000;23 Suppl 1:S80-2.
188. Csako G. Causes, consequences, and recognition of false-positive reactions for ketones. Clin Chem 1990;36:1388-9. (Pubitemid 20251961)
189. Rosenbloom AL, Malone JI. Recognition of impending ketoacidosis delayed by ketone reagent strip failure. JAMA 1978;240:2462-4.
190. McMurray CH, Blanchflower WJ, Rice DA. Automated kinetic method for D-3-hydroxybutyrate in plasma or serum. Clin Chem 1984;30:421-5.
191. Koch DD, Feldbruegge DH. Optimized kinetic method for automated determination of betahydroxybutyrate. Clin Chem 1987;33:1761-6. (Pubitemid 19097539)
192. D'arrigo T. Beyond blood glucose. Diabetes Forecast 1999;52:37-8.
193. Westphal SA. The occurrence of diabetic ketoacidosis in non-insulin-dependent diabetes and newly diagnosed diabetic adults. Am J Med 1996;101:19-24. (Pubitemid 26285936)
194. Wiggam MI, O'Kane MJ, Harper R, Atkinson AB, Hadden DR, Trimble ER, Bell PM. Treatment of diabetic ketoacidosis using normalization of blood 3-hydroxybutyrate concentration as the endpoint of emergency management. A randomized controlled study. Diabetes Care 1997;20:1347-52. (Pubitemid 27366804)
195. Umpierrez GE, Watts NB, Phillips LS. Clinical utility of beta-hydroxybutyrate determined by reflectance meter in the management of diabetic ketoacidosis. Diabetes Care 1995;18:137-8.
196. Noyes KJ, Crofton P, Bath LE, Holmes A, Stark L, Oxley CD, Kelnar CJ. Hydroxybutyrate nearpatient testing to evaluate a new end-point for intravenous insulin therapy in the treatment of diabetic ketoacidosis in children. Pediatr Diabetes 2007;8:150-6. (Pubitemid 46864296)
197. ADA. Implications of the Diabetes Control and Complications Trial [Position statement]. Diabetes Care 2000;23 Suppl 1:S24-6.
198. Kitzmiller JL, Block JM, Brown FM, Catalano PM, Conway DL, Coustan DR, et al. Managing preexisting diabetes for pregnancy: summary of evidence and consensus recommendations for care. Diabetes Care 2008;31:1060-79.
199. Davidson MB. Diabetes research and diabetes care. Where do we stand? Diabetes Care 1998;21:2152-60.
200. ADA. Provider Notes: the newsletter of the ADA/NCQA Provider Recognition Program. Provid Notes 2000;1:1-4.
201. Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, Zinman B. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2006;49:1711-21.
202. Qaseem A, Vijan S, Snow V, Cross JT, Weiss KB, Owens DK. Glycemic control and type 2 diabetes mellitus: the optimal hemoglobin A1c targets. A guidance statement from the American College of Physicians. Ann Intern Med 2007;147:417-22. (Pubitemid 351664542)
203. Bunn HF. Nonenzymatic glycosylation of protein: relevance to diabetes. Am J Med 1981;70:325-30. (Pubitemid 11146018)
204. Goldstein DE, Little RR, Wiedmeyer HM, England JD, McKenzie EM. Glycated hemoglobin: methodologies and clinical applications. Clin Chem 1986;32:B64-70.
205. Svendsen PA, Lauritzen T, Soegaard U, Nerup J. Glycosylated haemoglobin and steady-state mean blood glucose concentration in type 1 (insulin-dependent) diabetes. Diabetologia 1982;23:403-5. (Pubitemid 12037379)
206. Cefalu WT, Wang ZQ, Bell-Farrow A, Kiger FD, Izlar C. Glycohemoglobin measured by automated affinity HPLC correlates with both shortterm and long-term antecedent glycemia. Clin Chem 1994;40:1317-21. (Pubitemid 24205951)
207. Murata GH, Hoffman RM, Duckworth WC, Wendel CS, Shah JH. Contributions of weekly mean blood glucose values to hemoglobin A1c in insulin-treated type 2 diabetes: the Diabetes Outcomes in Veterans Study (DOVES). Am J Med Sci 2004;327:319-23. (Pubitemid 38780175)
208. Nathan DM, Turgeon H, Regan S. Relationship between glycated haemoglobin levels and mean glucose levels over time. Diabetologia 2007;50:2239-44. (Pubitemid 47512407)
209. Nathan DM, Kuenen J, Borg R, Zheng H, Schoenfeld D, Heine RJ. Translating the hemoglobin A1c assay into estimated average glucose values. Diabetes Care 2008;31:1473-8.
210. Baker JR, Johnson RN, Scott DJ. Serum fructosamine concentrations in patients with type II (non-insulin-dependent) diabetes mellitus during changes in management. Br Med J (Clin Res Ed) 1984;288:1484-6.
211. Tahara Y, Shima K. Kinetics of HbA1c, glycated albumin, and fructosamine and analysis of their weight functions against preceding plasma glucose level. Diabetes Care 1995;18:440-7.
212. Little RR, Wiedmeyer HM, England JD, Wilke AL, Rohlfing CL, Wians FH Jr, et al. Interlaboratory standardization of measurements of glycohemoglobins. Clin Chem 1992;38:2472-8. (Pubitemid 23006216)
213. Bodor GS, Little RR, Garrett N, Brown W, Goldstein DE, Nahm MH. Standardization of glycohemoglobin determinations in the clinical laboratory: three years of experience. Clin Chem 1992;38:2414-8. (Pubitemid 23006203)
214. Weykamp CW, Penders TJ, Muskiet FA, van der Slik W. Effect of calibration on dispersion of glycohemoglobin values determined by 111 laboratories using 21 methods. Clin Chem 1994; 40:138-44. (Pubitemid 24050226)
215. Goldstein DE, Little RR. Bringing order to chaos: the National Glycohemoglobin Standardization Program. Contemp Int Med 1997;9:27-32.
216. Little RR, Rohlfing CL, Wiedmeyer HM, Myers GL, Sacks DB, Goldstein DE. The National Glycohemoglobin Standardization Program: a five-year progress report. Clin Chem 2001;47:1985-92. (Pubitemid 33010715)
217. DCCT. Feasibility of centralized measurements of glycated hemoglobin in the Diabetes Control and Complications Trial: a multicenter study. Clin Chem 1987;33:2267-71.
218. Little RR, Rohlfing CL, Sacks DB. Status of HbA1c measurement and goals for improvement: from chaos to order for improving diabetes care. Clin Chem 2011;57:205-14.
219. Jeppsson JO, Kobold U, Barr J, Finke A, Hoelzel W, Hoshino T, et al. Approved IFCC reference method for the measurement of HbA1c in human blood. Clin Chem Lab Med 2002;40:78-89. (Pubitemid 34196455)
220. Hoelzel W, Weykamp C, Jeppsson JO, Miedema K, Barr JR, Goodall I, et al. IFCC reference system for measurement of hemoglobin A1c in human blood and the national standardization schemes in the United States, Japan, and Sweden: a method-comparison study. Clin Chem 2004;50:166-74. (Pubitemid 38125714)
221. Weykamp C, John WG, Mosca A, Hoshino T, Little R, Jeppsson J, et al. The IFCC reference measurement system for HbA1c: a 6-year progress report. Clin Chem 2008;54:240-8. (Pubitemid 351302616)
222. Sacks DB. Translating hemoglobin A1c into average blood glucose: Implications for clinical chemistry. Clin Chem 2008;54:1756-8.
223. Hanas R, John G. 2010 consensus statement on the worldwide standardization of the hemoglobin A1c measurement. Clin Chem 2010;56:1362-4.
224. Pani LN, Korenda L, Meigs JB, Driver C, Chamany S, Fox CS, et al. Effect of aging on A1C levels in individuals without diabetes: evidence from the Framingham Offspring Study and the National Health and Nutrition Examination Survey 2001-2004. Diabetes Care 2008;31:1991-6.
225. Ziemer DC, Kolm P, Weintraub WS, Vaccarino V, Rhee MK, Twombly JG, et al. Glucoseindependent, black-white differences in hemoglobin A1c levels: a cross-sectional analysis of 2 studies. Ann Intern Med 2010;152:770-7.
226. Little RR, Sacks DB. HbA1c: How do we measure it and what does it mean? Curr Opin Endocrinol Diabetes Obes 2009;16:113-8.
227. Herman WH, Ma Y, Uwaifo G, Haffner S, Kahn SE, Horton ES, et al. Differences in A1C by race and ethnicity among patients with impaired glucose tolerance in the Diabetes Prevention Program. Diabetes Care 2007;30:2453-7. (Pubitemid 47547771)
228. 1c levels for children and young adults in the U.S.: Third National Health and Nutrition Examination Survey. Diabetes Care 2002;25:1326-30.
229. Selvin E, Steffes MW, Zhu H, Matsushita K, Wagenknecht L, Pankow J, et al. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med 2010;362:800-11.
230. Davie SJ, Gould BJ, Yudkin JS. Effects of vitamin C on glycosylation of proteins. Diabetes 1992;41:167-73.
231. Ceriello A, Giugliano D, Quatraro A, Donzella C, Dipalo G, Lefebvre PJ. Vitamin E reduction of protein glycosylation in diabetes. New prospect for prevention of diabetic complications? Diabetes Care 1991;14:68-72.
232. Tarim O, Kucukerdogan A, Gunay U, Eralp O, Ercan I. Effects of iron deficiency anemia on hemoglobin A1c in type 1 diabetes mellitus. Pediatr Int 1999;41:357-62. (Pubitemid 29376974)
233. Bry L, Chen PC, Sacks DB. Effects of hemoglobin variants and chemically modified derivatives on assays for glycohemoglobin [Review]. Clin Chem 2001;47:153-63. (Pubitemid 32142912)
234. Roberts WL, Chiasera JM, Ward-Cook KM. Glycohemoglobin results in samples with hemoglobin C or S trait: a comparison of four test systems. Clin Chem 1999;45:906-9. (Pubitemid 29266625)
235. Weykamp CW, Penders TJ, Muskiet FA, van der Slik W. Influence of hemoglobin variants and derivatives on glycohemoglobin determinations, as investigated by 102 laboratories using 16 methods. Clin Chem 1993;39:1717-23. (Pubitemid 23246008)
236. Schnedl WJ, Krause R, Halwachs-Baumann G, Trinker M, Lipp RW, Krejs GJ. Evaluation of HbA1c determination methods in patients with hemoglobinopathies. Diabetes Care 2000;23:339-44. (Pubitemid 30131741)
237. Rendell M, Brannan C, Nierenberg J, Rasbold K, Hestorff T. Fingerstick glycosylated hemoglobin, plasma protein, and albumin. Diabetes Care 1987;10:629-32. (Pubitemid 17158938)
238. Ferrell RE, Hanis CL, Aguilar L, Tulloch B, Garcia C, Schull WJ. Glycosylated hemoglobin determination from capillary blood samples. Utility in an epidemiologic survey of diabetes. Am J Epidemiol 1984;119:159-66. (Pubitemid 14186710)
239. Little RR, England JD, Wiedmeyer HM, Goldstein DE. Effects of whole blood storage on results for glycosylated hemoglobin as measured by ionexchange chromatography, affinity chromatography, and colorimetry. Clin Chem 1983;29:1113-5. (Pubitemid 13106896)
240. Little RR, Rohlfing CL, Tennill AL, Connolly S, Hanson S. Effects of sample storage conditions on glycated hemoglobin measurement: evaluation of five different high performance liquid chromatography methods. Diabetes Technol Ther 2007;9:36-42.
241. Baglin SK, Brown AS. Two capillary blood-collection techniques for estimating glycohemoglobin compared. Clin Chem 1995;41:330-2.
242. Voss EM, Cembrowski GS, Clasen BL, Spencer ML, Ainslie MB, Haig B. Evaluation of capillary collection system for HbA1c specimens. Diabetes Care 1992;15:700-1.
243. Little RR, Wiedmeyer HM, Huang DH, Goldstein DE, Parson RG, Kowal R, et al. A simple blood collection device for analysis of glycohemoglobin (GHB). Clin Chem 1998;44:A139.
244. Baynes JW, Bunn HF, Goldstein D, Harris M, Martin DB, Peterson C, Winterhalter K. National Diabetes Data Group: report of the expert committee on glucosylated hemoglobin. Diabetes Care 1984;7:602-6. (Pubitemid 15210467)
245. Marshall SM, Barth JH. Standardization of HbA1c measurements: a consensus statement. Ann Clin Biochem 2000;37:45-6.
246. 1c analysis-precision, accuracy and standardisation: consensus statement of the Australasian Association of Clinical Biochemists (AACB), the Australian Diabetes Society (ADS), the Royal College of Pathologists of Australasia (RCPA), Endocrine Society of Australia (ESA), and the Australian Diabetes Educators Association (ADEA). Clin Chem Lab Med 2007;45:1083-97.
247. Sacks DB. CAP surveys: participant summary for glycohemoglobin survey 2010 set GH2-A. Northfield, IL: College of American Pathologists; 2010.
248. Goldstein DE, Peth SB, England JD, Hess RL, Da Costa J. Effects of acute changes in blood glucose on HbA1c. Diabetes 1980;29:623-8. (Pubitemid 12201308)
249. Cagliero E, Levina EV, Nathan DM. Immediate feedback of HbA1c levels improves glycemic control in type 1 and insulin-treated type 2 diabetic patients. Diabetes Care 1999;22:1785-9. (Pubitemid 29521862)
250. Kennedy L, Herman WH, Strange P, Harris A. Impact of active versus usual algorithmic titration of basal insulin and point-of-care versus laboratory measurement of HbA1c on glycemic control in patients with type 2 diabetes: the Glycemic Optimization with Algorithms and Labs at Point of Care (GOAL A1C) trial. Diabetes Care 2006;29:1-8. (Pubitemid 44033422)
251. Khunti K, Stone MA, Burden AC, Turner D, Raymond NT, Burden M, Baker R. Randomised controlled trial of near-patient testing for glycated haemoglobin in people with type 2 diabetes mellitus. Br J Gen Pract 2006;56:511-7. (Pubitemid 43984468)
252. Larsen ML, Horder M, Mogensen EF. Effect of long-term monitoring of glycosylated hemoglobin levels in insulin-dependent diabetes mellitus. N Engl J Med 1990;323:1021-5. (Pubitemid 20336960)
253. Davidson MB, Peters AL, Schriger DL. An alternative approach to the diagnosis of diabetes with a review of the literature. Diabetes Care 1995;18:1065-71.
254. Lenters-Westra E, Slingerland RJ. Six of eight hemoglobin A1c point-of-care instruments do not meet the general accepted analytical performance criteria. Clin Chem 2010;56:44-52.
255. American Association of Clinical Endocrinologists Board of Directors/American College of Endocrinologists Board of Trustees. American Association of Clinical Endocrinologists/American College of Endocrinology statement on the use of hemoglobin A1c for the diagnosis of diabetes. Endocr Pract 2010;16:155-6.
256. Makita Z, Radoff S, Rayfield EJ, Yang Z, Skolnik E, Delaney V, et al. Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med 1991;325:836-42.
257. Monnier VM, Bautista O, Kenny D, Sell DR, Fogarty J, Dahms W, et al. Skin collagen glycation, glycoxidation, and crosslinking are lower in subjects with long-term intensive versus conventional therapy of type 1 diabetes: relevance of glycated collagen products versus HbA1c as markers of diabetic complications. DCCT Skin Collagen Ancillary Study Group. Diabetes Control and Complications Trial. Diabetes 1999;48:870-80.
258. Murphy R, Ellard S, Hattersley AT. Clinical implications of a molecular genetic classification of monogenic beta-cell diabetes. Nat Clin Pract Endocrinol Metab 2008;4:200-13. (Pubitemid 351430925)
259. Edghill EL, Flanagan SE, Patch AM, Boustred C, Parrish A, Shields B, et al. Insulin mutation screening in 1,044 patients with diabetes: mutations in the INS gene are a common cause of neonatal diabetes but a rare cause of diabetes diagnosed in childhood or adulthood. Diabetes 2008;57:1034-42.
260. Stoy J, Greeley SA, Paz VP, Ye H, Pastore AN, Skowron KB, et al. Diagnosis and treatment of neonatal diabetes: a United States experience. Pediatr Diabetes 2008;9:450-9.
261. Fajans SS, Bell GI, Polonsky KS. Molecular mechanisms and clinical pathophysiology of maturity-onset diabetes of the young. N Engl J Med 2001;345:971-80.
262. Graham J, Hagopian WA, Kockum I, Li LS, Sanjeevi CB, Lowe RM, et al. Genetic effects on age-dependent onset and islet cell autoantibody markers in type 1 diabetes. Diabetes 2002;51:1346-55. (Pubitemid 34826598)
263. Concannon P, Rich SS, Nepom GT. Genetics of type 1A diabetes. N Engl J Med 2009;360:1646-54.
264. Nagi DK, Hendra TJ, Ryle AJ, Cooper TM, Temple RC, Clark PM, et al. The relationships of concentrations of insulin, intact proinsulin and 32-33 split proinsulin with cardiovascular risk factors in type 2 (non-insulin-dependent) diabetic subjects. Diabetologia 1990;33:532-7. (Pubitemid 20293159)
265. Barrett JC, Clayton DG, Concannon P, Akolkar B, Cooper JD, Erlich HA, et al. Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes. Nat Genet 2009;41:703-7.
266. Nadler ST, Stoehr JP, Schueler KL, Tanimoto G, Yandell BS, Attie AD. The expression of adipogenic genes is decreased in obesity and diabetes mellitus. Proc Natl Acad Sci U S A 2000;97:11371-6.
267. Ziegler AG, Bachmann W, Rabl W. Prophylactic insulin treatment in relatives at high risk for type 1 diabetes. Diabetes Metab Rev 1993;9:289-93. (Pubitemid 24160208)
268. Rewers M, Bugawan TL, Norris JM, Blair A, Beaty B, Hoffman M, et al. Newborn screening for HLA markers associated with IDDM: Diabetes Autoimmunity Study in the Young (DAISY). Diabetologia 1996;39:807-12. (Pubitemid 26228110)
269. Hagopian WA, Lernmark A, Rewers MJ, Simell OG, She JX, Ziegler AG, et al. TEDDY - The Environmental Determinants of Diabetes in the Young: an observational clinical trial. Ann N Y Acad Sci 2006;1079:320-6. (Pubitemid 44968741)
270. Kukreja A, Maclaren NK. Autoimmunity and diabetes. J Clin Endocrinol Metab 1999;84:4371-8.
271. Barker JM, Goehrig SH, Barriga K, Hoffman M, Slover R, Eisenbarth GS, et al. Clinical characteristics of children diagnosed with type 1 diabetes through intensive screening and followup. Diabetes Care 2004;27:1399-404. (Pubitemid 38679990)
272. Saxena R, Voight BF, Lyssenko V, Burtt NP, de Bakker PI, Chen H, et al. Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science 2007;316:1331-6. (Pubitemid 46871653)
273. Scott LJ, Mohlke KL, Bonnycastle LL, Willer CJ, Li Y, Duren WL, et al. A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science 2007;316:1341-5. (Pubitemid 46871655)
274. Meigs JB, Shrader P, Sullivan LM, McAteer JB, Fox CS, Dupuis J, et al. Genotype score in addition to common risk factors for prediction of type 2 diabetes. N Engl J Med 2008;359:2208-19.
275. Klein J, Sato A. The HLA system. First of two parts. N Engl J Med 2000;343:702-9.
276. Taylor SI, Arioglu E. Genetically defined forms of diabetes in children. J Clin Endocrinol Metab 1999;84:4390-6.
277. Fajans SS, Bell GI, Bowden DW, Halter JB, Polonsky KS. Maturity onset diabetes of the young (MODY). Diabet Med 1996;13:S90-5.
278. Todd JA. Genetics of type 1 diabetes. Pathol Biol (Paris) 1997;45:219-27. (Pubitemid 27207335)
279. Atkinson MA, Eisenbarth GS. Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet 2001;358:221-9. (Pubitemid 32718550)
280. Harrison LC. Risk assessment, prediction and prevention of type 1 diabetes. Pediatr Diabetes 2001;2:71-82. (Pubitemid 32577161)
281. Redondo MJ, Kawasaki E, Mulgrew CL, Noble JA, Erlich HA, Freed BM, et al. DR-and DQ-associated protection from type 1A diabetes: comparison of DRB1*1401 and DQA1*0102-DQB1*0602*. J Clin Endocrinol Metab 2000;85:3793-7.
282. Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007;447:661-78.
283. Todd JA, Walker NM, Cooper JD, Smyth DJ, Downes K, Plagnol V, et al. Robust associations of four new chromosome regions from genomewide analyses of type 1 diabetes. Nat Genet 2007;39:857-64. (Pubitemid 47018195)
284. Maclaren NK, Kukreja A. Type 1 diabetes. In: Sly WS, ed. The metabolic and molecular bases of inherited disease. 8th ed. St. Louis: McGraw-Hill; 2001. p 1471-88.
285. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998;15:539-53.
286. Palmer JP, Asplin CM, Clemons P, Lyen K, Tatpati O, Raghu PK, Paquette TL. Insulin antibodies in insulin-dependent diabetics before insulin treatment. Science 1983;222:1337-9. (Pubitemid 14204704)
287. Baekkeskov S, Aanstoot HJ, Christgau S, Reetz A, Solimena M, Cascalho M, et al. Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase. Nature 1990;347:151-6; erratum 1990;347:728.
288. Kaufman DL, Erlander MG, Clare-Salzler M, Atkinson MA, Maclaren NK, Tobin AJ. Autoimmunity to two forms of glutamate decarboxylase in insulin-dependent diabetes mellitus. J Clin Invest 1992;89:283-92.
289. Atkinson MA, Maclaren NK. Islet cell autoantigens in insulin-dependent diabetes. J Clin Invest 1993;92:1608-16. (Pubitemid 23304521)
290. Lan MS, Wasserfall C, Maclaren NK, Notkins AL. IA-2, a transmembrane protein of the protein tyrosine phosphatase family, is a major autoantigen in insulin-dependent diabetes mellitus. Proc Natl Acad Sci U S A 1996;93:6367-70. (Pubitemid 26230311)
291. Lu J, Li Q, Xie H, Chen ZJ, Borovitskaya AE, Maclaren NK, et al. Identification of a second transmembrane protein tyrosine phosphatase, IA-2beta, as an autoantigen in insulindependent diabetes mellitus: precursor of the 37-kDa tryptic fragment. Proc Natl Acad Sci U S A 1996;93:2307-11.
292. Wenzlau JM, Juhl K, Yu L, Moua O, Sarkar SA, Gottlieb P, et al. The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. Proc Natl Acad Sci U S A 2007;104:17040-5. (Pubitemid 350210987)
293. Wenzlau JM, Liu Y, Yu L, Moua O, Fowler KT, Rangasamy S, et al. A common nonsynonymous single nucleotide polymorphism in the SLC30A8 gene determines ZnT8 autoantibody specificity in type 1 diabetes. Diabetes 2008;57:2693-7.
294. Patterson CC, Dahlquist GG, Gyurus E, Green A, Soltesz G. Incidence trends for childhood type 1 diabetes in Europe during 1989-2003 and predicted new cases 2005-20: a multicentre prospective registration study. Lancet 2009;373:2027-33.
295. Maclaren N, Lan M, Coutant R, Schatz D, Silverstein J, Muir A, et al. Only multiple autoantibodies to islet cells (ICA), insulin, GAD65, IA-2 and IA-2beta predict immune-mediated (type 1) diabetes in relatives. J Autoimmun 1999;12:279-87. (Pubitemid 29261964)
296. Verge CF, Gianani R, Kawasaki E, Yu L, Pietropaolo M, Jackson RA, et al. Prediction of type I diabetes in first-degree relatives using a combination of insulin, GAD, and ICA512bdc/IA-2 autoantibodies. Diabetes 1996;45:926-33. (Pubitemid 26225509)
297. Schott M, Schatz D, Atkinson M, Krischer J, Mehta H, Vold B, Maclaren N. GAD65 autoantibodies increase the predictability but not the sensitivity of islet cell and insulin autoantibodies for developing insulin dependent diabetes mellitus. J Autoimmun 1994;7:865-72. (Pubitemid 24378370)
298. Turner R, Stratton I, Horton V, Manley S, Zimmet P, Mackay IR, et al. UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. UK Prospective Diabetes Study Group [published erratum appears in Lancet 1998;351:376]. Lancet 1997;350:1288-93.
299. Pozzilli P, Di Mario U. Autoimmune diabetes not requiring insulin at diagnosis (Latent Autoimmune Diabetes of the Adult): definition, characterization, and potential prevention. Diabetes Care 2001;24:1460-7. (Pubitemid 33716438)
300. Palmer JP, Hampe CS, Chiu H, Goel A, Brooks-Worrell BM. Is latent autoimmune diabetes in adults distinct from type 1 diabetes or just type 1 diabetes at an older age? Diabetes 2005;54(Suppl 2):S62-7.
301. Kobayashi T, Tanaka S, Harii N, Aida K, Shimura H, Ohmori M, et al. Immunopathological and genetic features in slowly progressive insulindependent diabetes mellitus and latent autoimmune diabetes in adults. Ann N Y Acad Sci 2006;1079:60-6. (Pubitemid 44968702)
302. Braghi S, Bonifacio E, Secchi A, Di Carlo V, Pozza G, Bosi E. Modulation of humoral islet autoimmunity by pancreas allotransplantation influences allograft outcome in patients with type 1 diabetes. Diabetes 2000;49:218-24. (Pubitemid 30071000)
303. Zimmet P, Turner R, McCarty D, Rowley M, Mackay I. Crucial points at diagnosis. Type 2 diabetes or slow type 1 diabetes. Diabetes Care 1999;22(Suppl 2):B59-64.
304. Petersen JS, Dyrberg T, Damm P, Kuhl C, Molsted-Pedersen L, Buschard K. GAD65 autoantibodies in women with gestational or insulin dependent diabetes mellitus diagnosed during pregnancy. Diabetologia 1996;39:1329-33. (Pubitemid 26356062)
305. Fuchtenbusch M, Ferber K, Standl E, Ziegler AG. Prediction of type 1 diabetes postpartum in patients with gestational diabetes mellitus by combined islet cell autoantibody screening: a prospective multicenter study. Diabetes 1997;46:1459-67. (Pubitemid 27369084)
306. Diabetes Prevention Trial - Type 1 Study Group. Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med 2002;346:1685-91.
307. Siljander H, Harkonen T, Hermann R, Simell S, Hekkala A, Salonsaari RT, et al. Role of insulin autoantibody affinity as a predictive marker for type 1 diabetes in young children with HLA-conferred disease susceptibility. Diabetes Metab Res Rev 2009;25:615-22.
308. Williams AJ, Bingley PJ, Bonifacio E, Palmer JP, Gale EA. A novel micro-assay for insulin autoantibodies. J Autoimmun 1997;10:473-8. (Pubitemid 27433643)
309. Bingley PJ, Bonifacio E, Mueller PW. Diabetes Antibody Standardization Program: first assay proficiency evaluation. Diabetes 2003;52:1128-36. (Pubitemid 36523346)
310. Grubin CE, Daniels T, Toivola B, Landin-Olsson M, Hagopian WA, Li L, et al. A novel radioligand binding assay to determine diagnostic accuracy of isoform-specific glutamic acid decarboxylase antibodies in childhood IDDM. Diabetologia 1994;37:344-50. (Pubitemid 24113564)
311. Torn C, Mueller PW, Schlosser M, Bonifacio E, Bingley PJ. Diabetes Antibody Standardization Program: evaluation of assays for autoantibodies to glutamic acid decarboxylase and islet antigen-2. Diabetologia 2008;51:846-52.
312. Mire-Sluis AR, Gaines Das R, Lernmark A. The World Health Organization International Collaborative Study for islet cell antibodies. Diabetologia 2000;43:1282-92.
313. Gleichmann H, Bottazzo GF. Progress toward standardization of cytoplasmic islet cellantibody assay. Diabetes 1987;36:578-84. (Pubitemid 18024731)
314. Verge CF, Stenger D, Bonifacio E, Colman PG, Pilcher C, Bingley PJ, Eisenbarth GS. Combined use of autoantibodies (IA-2 autoantibody, GAD autoantibody, insulin autoantibody, cytoplasmic islet cell antibodies) in type 1 diabetes: Combinatorial Islet Autoantibody Workshop. Diabetes 1998;47:1857-66. (Pubitemid 28549191)
315. Ellis TM, Schatz DA, Ottendorfer EW, Lan MS, Wasserfall C, Salisbury PJ, et al. The relationship between humoral and cellular immunity to IA-2 in IDDM. Diabetes 1998;47:566-9. (Pubitemid 28160446)
316. Atkinson MA, Bowman MA, Campbell L, Darrow BL, Kaufman DL, Maclaren NK. Cellular immunity to a determinant common to glutamate decarboxylase and coxsackie virus in insulin-dependent diabetes [see comments]. J Clin Invest 1994;94:2125-9. (Pubitemid 24348254)
317. Skyler JS, Krischer JP, Wolfsdorf J, Cowie C, Palmer JP, Greenbaum C, et al. Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial - Type 1. Diabetes Care 2005;28:1068-76. (Pubitemid 40616615)
318. Nanto-Salonen K, Kupila A, Simell S, Siljander H, Salonsaari T, Hekkala A, et al. Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial. Lancet 2008;372:1746-55.
319. Agardh CD, Cilio CM, Lethagen A, Lynch K, Leslie RD, Palmer M, et al. Clinical evidence for the safety of GAD65 immunomodulation in adult-onset autoimmune diabetes. J Diabetes Complications 2005;19:238-46. (Pubitemid 40910206)
320. Lernmark A, Agardh CD. Immunomodulation with human recombinant autoantigens. Trends Immunol 2005;26:608-12. (Pubitemid 41726449)
321. ADA. Diabetes nephropathy. Diabetes Care 1999;22(Suppl 1):S66-9.
322. Davidson MB, Bazargan M, Bakris G, Peters Harmel A, Campese V, Basta E. ImmunoDip: an improved screening method for microalbuminuria. Am J Nephrol 2004;24:284-8. (Pubitemid 39070110)
323. Khosla N, Sarafidis PA, Bakris GL. Microalbuminuria. Clin Lab Med 2006;26:635-53, vi-vii.
324. Sarafidis PA, Riehle J, Bogojevic Z, Basta E, Chugh A, Bakris GL. A comparative evaluation of various methods for microalbuminuria screening. Am J Nephrol 2008;28:324-9.
325. Levey AS, de Jong PE, Coresh J, Nahas ME, Astor BC, Matsushita K, et al. The definition, classification and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int [Epub ahead of print 2010 Dec 8].
326. KDOQI. KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis 2007;49:S12-154.
327. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42:1206-52. (Pubitemid 37553153)
328. Klausen KP, Scharling H, Jensen JS. Very low level of microalbuminuria is associated with increased risk of death in subjects with cardiovascular or cerebrovascular diseases. J Intern Med 2006;260:231-7. (Pubitemid 44253636)
329. Klausen KP, Scharling H, Jensen G, Jensen JS. New definition of microalbuminuria in hypertensive subjects: association with incident coronary heart disease and death. Hypertension 2005;46:33-7. (Pubitemid 40946487)
330. Ratto E, Leoncini G, Viazzi F, Vaccaro V, Parodi A, Falqui V, et al. Microalbuminuria and cardiovascular risk assessment in primary hypertension: should threshold levels be revised? Am J Hypertens 2006;19:728-34; discussion 735-6.
331. Wachtell K, Ibsen H, Olsen MH, Borch-Johnsen K, Lindholm LH, Mogensen CE, et al. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann Intern Med 2003;139:901-6.
332. Rachmani R, Levi Z, Lidar M, Slavachevski I, Half-Onn E, Ravid M. Considerations about the threshold value of microalbuminuria in patients with diabetes mellitus: lessons from an 8-year follow-up study of 599 patients. Diabetes Res Clin Pract 2000;49:187-94. (Pubitemid 30665465)
333. Pambianco G, Costacou T, Orchard TJ. The prediction of major outcomes of type 1 diabetes: a 12-year prospective evaluation of three separate definitions of the metabolic syndrome and their components and estimated glucose disposal rate: the Pittsburgh Epidemiology of Diabetes Complications Study experience. Diabetes Care 2007;30:1248-54. (Pubitemid 46684655)
334. Witte EC, Lambers Heerspink HJ, de Zeeuw D, Bakker SJ, de Jong PE, Gansevoort R. First morning voids are more reliable than spot urine samples to assess microalbuminuria. J Am Soc Nephrol 2009;20:436-43.
335. Levey AS, Coresh J, Greene T, Marsh J, Stevens LA, Kusek JW, Van Lente F. Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem 2007;53:766-72. (Pubitemid 46580250)
336. Vassalotti JA, Stevens LA, Levey AS. Testing for chronic kidney disease: a position statement from the National Kidney Foundation. Am J Kidney Dis 2007;50:169-80. (Pubitemid 47095094)
337. Kistorp C, Raymond I, Pedersen F, Gustafsson F, Faber J, Hildebrandt P. N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. JAMA 2005;293:1609-16.
338. Yuyun MF, Khaw KT, Luben R, Welch A, Bingham S, Day NE, Wareham NJ. Microalbuminuria independently predicts all-cause and cardiovascular mortality in a British population: The European Prospective Investigation into Cancer in Norfolk (EPIC-Norfolk) population study. Int J Epidemiol 2004;33:189-98. (Pubitemid 38500176)
339. Weir MR, Bakris GL. Editorial perspective. Should microalbuminuria ever be considered as a renal endpoint in any clinical trial? Am J Nephrol 2010;31:469-70.
340. Glassock RJ. Debate: CON position. Should microalbuminuria ever be considered as a renal endpoint in any clinical trial? Am J Nephrol 2010;31:462-5; discussion 466-7.
341. Steinke JM, Sinaiko AR, Kramer MS, Suissa S, Chavers BM, Mauer M. The early natural history of nephropathy in type 1 diabetes: III. Predictors of 5-year urinary albumin excretion rate patterns in initially normoalbuminuric patients. Diabetes 2005;54:2164-71.
342. Duka I, Bakris G. Influence of microalbuminuria in achieving blood pressure goals. Curr Opin Nephrol Hypertens 2008;17:457-63.
343. Schrier RW, Estacio RO, Mehler PS, Hiatt WR. Appropriate blood pressure control in hypertensive and normotensive type 2 diabetes mellitus: a summary of the ABCD trial. Nat Clin Pract Nephrol 2007;3:428-38. (Pubitemid 47123588)
344. Ruggenenti P, Fassi A, Ilieva AP, Bruno S, Iliev IP, Brusegan V, et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004;351:1941-51. (Pubitemid 39447135)
345. Sinzinger H, Kritz H, Furberg CD. Atorvastatin reduces microalbuminuria in patients with familial hypercholesterolemia and normal glucose tolerance. Med Sci Monit 2003;9:PI88-92.
346. Incerti J, Zelmanovitz T, Camargo JL, Gross JL, de Azevedo MJ. Evaluation of tests for mi- croalbuminuria screening in patients with diabetes. Nephrol Dial Transplant 2005;20:2402-7. (Pubitemid 41548863)
347. Lepore G, Maglio ML, Nosari I, Dodesini AR, Trevisan R. Cost-effectiveness of two screening programs for microalbuminuria in type 2 diabetes. Diabetes Care 2002;25:2103-4; author reply 2104.
348. Roberts WL, Calcote CB, Cook CB, Gordon DL, Moore ML, Moore S, et al. Comparison of four commercial urinary albumin (microalbumin) methods: implications for detecting diabetic nephropathy using random urine specimens. Clin Chim Acta 1998;273:21-33.
349. Howey JE, Browning MC, Fraser CG. Biologic variation of urinary albumin: consequences for analysis, specimen collection, interpretation of results, and screening programs. Am J Kidney Dis 1989;13:35-7. (Pubitemid 19035823)
350. Gansevoort RT, Verhave JC, Hillege HL, Burgerhof JG, Bakker SJ, de Zeeuw D, de Jong PE. The validity of screening based on spot morning urine samples to detect subjects with microalbuminuria in the general population. Kidney Int Suppl 2005:S28-35.
351. Meinhardt U, Ammann RA, Fluck C, Diem P, Mullis PE. Microalbuminuria in diabetes mellitus: efficacy of a new screening method in comparison with timed overnight urine collection. J Diabetes Complications 2003;17:254-7. (Pubitemid 37040771)
352. Poulsen PL, Hansen B, Amby T, Terkelsen T, Mogensen CE. Evaluation of a dipstick test for microalbuminuria in three different clinical settings, including the correlation with urinary albumin excretion rate. Diabetes Metab 1992;18:395-400. (Pubitemid 23045749)
353. Fernández-Fernández I, Páez Pinto JM, Hermosín Bono T, Vázquez Garijo P, Ortiz Camuñez MA, Tarilonte Delgado MA. Rapid screening test evaluation for microalbuminuria in diabetes mellitus. Acta Diabetol 1998;35:199-202. (Pubitemid 29047934)
354. Leong SO, Lui KF, Ng WY, Thai AC. The use of semi-quantitative urine test-strip (Micral Test) for microalbuminuria screening in patients with diabetes mellitus. Singapore Med J 1998;39:101-3. (Pubitemid 128518492)
355. Shaikh A, Seegmiller JC, Borland TM, Burns BE, Ladwig PM, Singh RJ, et al. Comparison between immunoturbidimetry, size-exclusion chromatography, and LC-MS to quantify urinary albumin. Clin Chem 2008;54:1504-10.
356. Lambers Heerspink HJ, Gansevoort RT, Brenner BM, Cooper ME, Parving HH, Shahinfar S, de Zeeuw D. Comparison of different measures of urinary protein excretion for prediction of renal events. J Am Soc Nephrol 2010;21:1355-60.
357. Ibsen H, Olsen MH, Wachtell K, Borch-Johnsen K, Lindholm LH, Mogensen CE, et al. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension 2005;45:198-202. (Pubitemid 40179960)
358. Collins AC, Sethi M, MacDonald FA, Brown D, Viberti GC. Storage temperature and differing methods of sample preparation in the measurement of urinary albumin. Diabetologia 1993;36:993-7. (Pubitemid 23288766)
359. MacNeil ML, Mueller PW, Caudill SP, Steinberg KK. Considerations when measuring urinary albumin: precision, substances that may interfere, and conditions for sample storage. Clin Chem 1991;37:2120-3. (Pubitemid 21925911)
360. Hishiki S, Tochikubo O, Miyajima E, Ishii M. Circadian variation of urinary microalbumin excretion and ambulatory blood pressure in patients with essential hypertension. J Hypertens 1998;16:2101-8. (Pubitemid 29002394)
361. Holl RW, Grabert M, Thon A, Heinze E. Urinary excretion of albumin in adolescents with type 1 diabetes: persistent versus intermittent microalbuminuria and relationship to duration of diabetes, sex, and metabolic control. Diabetes Care 1999;22:1555-60. (Pubitemid 29418255)
362. Despres JP, Lamarche B, Mauriege P, Cantin B, Dagenais GR, Moorjani S, Lupien PJ. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996;334:952-7. (Pubitemid 26114161)
363. Reaven GM. Insulin resistance and its consequences; non-insulin dependent diabetes mellitus and coronary heart disease. In: LeRoith D, Taylor SI, Olefsky JM, eds. Diabetes mellitus: a fundamental clinical text. Philadelphia: Lippincott-Raven; 1996. p 509-19.
364. Chevenne D, Trivin F, Porquet D. Insulin assays and reference values. Diabetes Metab 1999;25:459-76. (Pubitemid 30003159)
365. Del Prato S. Measurement of insulin resistance in vivo. Drugs 1999;58:3-6; discussion 75-82.
366. Wilson PW, Meigs JB, Sullivan L, Fox CS, Nathan DM, D'Agostino RB Sr. Prediction of incident diabetes mellitus in middle-aged adults: the Framingham Offspring Study. Arch Intern Med 2007;167:1068-74. (Pubitemid 46835795)
367. Rutter MK, Wilson PW, Sullivan LM, Fox CS, D'Agostino RB Sr, Meigs JB. Use of alternative thresholds defining insulin resistance to predict incident type 2 diabetes mellitus and cardiovascular disease. Circulation 2008;117:1003-9.
368. Marks V. Recognition and differential diagnosis of spontaneous hypoglycaemia. Clin Endocrinol (Oxf) 1992;37:309-16.
369. Marks V, Teale JD. Hypoglycemia: factitious and felonious. Endocrinol Metab Clin North Am 1999;28:579-601. (Pubitemid 29441323)
370. American College of Obstetrics and Gynecology. ACOG practice bulletin. Polycycstic ovary syndrome. Number 41, December 2002. Int J Gynaecol Obstet 2003;80:335-48.
371. Robbins DC, Andersen L, Bowsher R, Chance R, Dinesen B, Frank B, et al. Report of the American Diabetes Association's Task Force on Standardization of the Insulin Assay. Diabetes 1996;45:242-56.
372. Marcovina S, Bowsher RR, Miller WG, Staten M, Myers G, Caudill SP, et al. Standardization of insulin immunoassays: report of the American Diabetes Association Workgroup. Clin Chem 2007;53:711-6. (Pubitemid 46580242)
373. Miller WG, Thienpont LM, Van Uytfanghe K, Clark PM, Lindstedt P, Nilsson G, Steffes MW. Toward standardization of insulin immunoassays. Clin Chem 2009;55:1011-8.
374. Staten MA, Stern MP, Miller WG, Steffes MW, Campbell SE. Insulin assay standardization: leading to measures of insulin sensitivity and secretion for practical clinical care. Diabetes Care 2010;33:205-6.
375. Little RR, Rohlfing CL, Tennill AL, Madsen RW, Polonsky KS, Myers GL, et al. Standardization of C-peptide measurements. Clin Chem 2008;54:1023-6. (Pubitemid 351793409)
376. Centers for Medicare and Medicaid Services. Infusion pumps: C-peptide levels as a criterion for use. https://www.cms.gov/transmittals/downloads/ R513CP.pdf (Accessed March 2008).
377. Burge MR, Schade DS. Insulins. Endocrinol Metab Clin North Am 1997;26:575-98.
378. ADA. Diagnosis and classification of diabetes mellitus. Diabetes Care 2010;33(Suppl 1):S62-9.